Table 1 Patient demographics and baseline characteristics.

From: Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Characteristic, N (%) unless stated

Total N = 47

Sex

 Male

0

 Female

47 (100)

Ethnicity

 Caucasian/White

41 (87.2)

 Non-Caucasian/non-White

3 (6.4)

Age, years; median (range)

48.0 (35–73)

Baseline ECOG PS

 0

25 (53.2)

 1

22 (46.8)

Prior anticancer therapy

 Chemotherapy

45 (95.7)

 Immunotherapy

1 (2.1)

 Other

11 (23.4)

 Missing

2 (4.3)

Number of previous anticancer therapy regimens

 Neoadjuvant

16 (34.0)

 Adjuvant

27 (57.4)

 1st line, metastatic disease

24 (51.1)

 2nd line, metastatic disease

10 (21.3)

 >2nd line, metastatic disease

5 (10.6)

 Missing

2 (4.3)

TP53a

 Wild type

2 (4.3)

 Mutant

34 (72.3)

 Missing

11 (23.4)

BRCA1/2b

 Wild type

31 (66)

 Mutant

5 (10.6)

 Missing

11 (23.4)

Basal subtypec

 Yes

36 (76.6)

 No

7 (14.9)

 Missing

4 (8.5)

  1. ATM ataxia-telangiectasia mutated, BRCA1/2 breast cancer gene 1/2, ECOG PS Eastern Cooperative Oncology Group Performance Status, TP53 tumor protein 53.
  2. aOnly patients with biomarker status determined by FoundationOne® CDx next generation sequencing were reported.
  3. bPatients with unknown BRCA1/2 status were prospectively tested at screening by BRCAnalysis assay (Myriad Genetics); patients that were found to be BRCA1/2 germline mutant were still enrolled in the study.
  4. cAssessment for basal subtype was performed retrospectively via PAM50 analysis (Prosigna).
Back to article page